Compare LASE & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASE | PMVP |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.3M | 66.1M |
| IPO Year | 2021 | 2020 |
| Metric | LASE | PMVP |
|---|---|---|
| Price | $0.69 | $1.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 520.1K |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $721,185.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $1.02 |
| 52 Week High | $5.88 | $1.88 |
| Indicator | LASE | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 26.96 | 65.59 |
| Support Level | $0.56 | $1.36 |
| Resistance Level | $1.22 | $1.50 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 2.73 | 95.45 |
Laser Photonics Corp is an integrated manufacturing company for photonics-based industrial products and solutions, laser cleaning technologies. Its laser-blasting technologies are focused on disrupting the sandblasting and abrasive blasting markets. The company offers a portfolio of integrated laser-blasting solutions for corrosion control, rust removal, de-coating, pre-welding and post-welding, laser cleaning, and surface conditioning. Its laser-blasting solutions are applicable in every industry dealing with materials processing, including automotive, aerospace, healthcare, consumer products, shipbuilding, machine manufacturing, nuclear maintenance and decommissioning, and surface coating. Geographically, the company generates almost all of its revenue from the domestic market.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.